Evidence map›Paper›PMID 41807414›Full record

ArticleNature communications2026

A meta learning and task adaptive approach for drug target affinity prediction.

Mengxuan Wan, Yanpeng Zhao, Yixin Zhang, Huiyan Xu, Duoyun Yi, Peng Zan, Song He, Xiaochen Bo

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mengxuan Wan *School of Medicine, Shanghai University, Shanghai, China.
Yanpeng Zhao *School of Medicine, Shanghai University, Shanghai, China.ORCID http://orcid.org/0000-0002-2117-630X
Yixin Zhang *Academy of Military Medical Sciences, Beijing, China.
Huiyan XuAcademy of Military Medical Sciences, Beijing, China.
Duoyun YiAcademy of Military Medical Sciences, Beijing, China.
Peng ZanSchool of Medicine, Shanghai University, Shanghai, China. zanpeng@shu.edu.cn.ORCID http://orcid.org/0000-0003-2588-2188
Song HeAcademy of Military Medical Sciences, Beijing, China. hes1224@163.com.ORCID http://orcid.org/0000-0002-4136-6151
Xiaochen BoAcademy of Military Medical Sciences, Beijing, China. boxc@bmi.ac.cn.ORCID http://orcid.org/0000-0003-1911-7922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate and robust prediction of drug-target affinity (DTA) plays a critical role in drug discovery. While deep learning has advanced DTA prediction, existing methods struggle with limited training data and poor generalization. In this study, we propose AdaMBind, a novel DTA prediction model based on meta-learning framework with an adaptive task module designed for low-data scenarios. It employs a dynamic "easy-to-hard" task scheduling mechanism to enhance training efficiency and robustness. Experimental results on three benchmark datasets demonstrate that AdaMBind outperforms 8 baseline models in predicting affinity for unseen targets, particularly under few-shot conditions. Under stringent data constraints, the model successfully identifies high-affinity compounds for ESR and TP53, achieving outstanding virtual screening performance. Furthermore, when applied to inhibitor discovery against FLT3 for acute myeloid leukemia, AdaMBind successfully identified candidate compounds with potent inhibitory activity, as verified by preliminary experimental assays. In summary, AdaMBind provides a robust framework for few-shot DTA prediction.

Indexed as

Drug DiscoveryAdaptive AlgorithmsDeep Learningfms-Like Tyrosine Kinase 3HumansPrediction AlgorithmsPredictive Learning ModelsTumor Suppressor Protein p53fms-Like Tyrosine Kinase 3Tumor Suppressor Protein p53

Identifiers

PMID41807414
PMCPMC13102954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.